Author Archives:

Survey: How our scientists use social media

Posted on February 12, 2012

We recently surveyed our scientists and some of their partners around the world: How are you using social media for science-related activities? The results show that respondents believe there is a place for social media in science, especially in the … Continue reading →

Posted in R&D, Social Media | 4 Comments

Editorial: Young Health Program “steeped in science”

Posted on January 24, 2012

This morning, our hometown newspaper lays out the challenges that are at the very heart of a new initiative – the Young Health Program: IM40 – we launched last week with the United Way of Delaware. From an editorial in the … Continue reading →

Posted in Young Health Program

Young Health Program: A partnership for Delaware

Posted on January 23, 2012

The News Journal of Delaware published a joint OpEd by Marion McCourt, chief operating officer of AstraZeneca US, and Michelle Taylor, president and chief executive officer of the United Way of Delaware. McCourt and Taylor present our partnership on a … Continue reading →

Posted in Young Health Program

AstraZeneca backs counterfeit drug legislation

Posted on January 19, 2012

AstraZeneca sent a letter to members of Congress today to express support for legislation that would increase penalties for those convicted of counterfeiting prescription medicines. The letters sent to bill sponsors Rep. Patrick Meehan, Sen. Patrick Leahy, Sen. Chuck Grassley … Continue reading →

Posted in Legislation | Tagged | 2 Comments

Fante to lead NPC, focusing on evidence-based medicine

Posted on November 3, 2011

As part of an ongoing series, we are taking a look at how evidence can help us identify the health and cost impact of treatments on patients, while also highlighting areas of unmet patient needs. Earlier posts can be found here and here. Rich Fante, … Continue reading →

Posted in AstraZeneca News, Real-world evidence

Access, affordability and one patient’s experience

Posted on October 26, 2011

Philadelphia Inquirer columnist Lisa Scottoline recently wrote about her experience in trying to access one of our medicines – CRESTOR® (rosuvastatin calcium). It is a frustrating – and all too common – example of someone trying to follow her doctor’s … Continue reading →

Posted in Patient Assistance, Patients

Medicaid, budgets and patients: What must be done

Posted on October 25, 2011

Editor’s note: Last week, we ran a four-part series on proposals in several states that would change the way they administer the pharmacy benefit in their Medicaid programs – transitioning from traditional fee-for-service Medicaid to a managed care model. Here is … Continue reading →

Posted in Legislation, Medicaid, Public Policy

Cardiovascular disease and pharma: A view from Europe

Posted on October 20, 2011

With cardiovascular disease (CVD) continuing to be the world’s leading killer, we wanted to see if AstraZeneca was on the right track in demonstrating our commitment to patients in this disease category. According to the results of a new survey … Continue reading →

Posted in R&D

Medicaid, budgets and patients part four: Patient protections

Posted on October 20, 2011

This week, we are taking a look at proposals in several states that would change the way they administer the pharmacy benefit in their Medicaid programs – transitioning from traditional fee-for-service Medicaid to a managed care model. Today we look … Continue reading →

Posted in Legislation, Medicaid, Patients, Public Policy | Tagged | 1 Comment

Medicaid, budgets and patients part three: Patients at risk

Posted on October 19, 2011

This week, we are taking a look at proposals in several states that would change the way they administer the pharmacy benefit in their Medicaid programs – transitioning from traditional fee-for-service Medicaid to a managed care model. Today we look … Continue reading →

Posted in Legislation, Medicaid, Patients, Public Policy | Tagged | 2 Comments